NEW YORK, Aug. 1 - A preliminary study published in the Aug. 2 issue of The Lancet reported that a gene expression profiling technique using microarrays could predict which breast cancer sufferers would respond to chemotherapy.
The study, which was partially funded by Aventis, was conducted over two years and involved 24 women receiving docetaxel, a common breast cancer chemotherapy drug. Scientists used arrays to find 92 genes that correlated with docetaxel response. This group of genes positively predicted drug response 92 percent of the time.
This was the first study to successfully predict chemotherapy response in breast cancer using this technique, according to Jeff Boyd, director of the Gynecology and Breast Cancer Research Laboratory at